GlassScriptPhysician profile
Nayeh E Mirshed
NPI 1689662892
$14,063.29
in general payments reported to CMS, 2019-2025
33 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,813 · 2020: $1,739 · 2021: $1,944 · 2022: $1,967 · 2023: $2,216 · 2024: $1,896 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,457 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.84 |
| Education | $143.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,848.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,798.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,606.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,273.24 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $1,246.65 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $1,134.98 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $806.62 | 2019-2025 | |
| Pfizer INC. | $650.89 | 2019-2025 | |
| Abbvie INC. | $593.88 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $504.64 | 2019-2023 | Steglatro |
| Amgen INC. | $473.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $382.16 | 2019-2023 | |
| Exact Sciences Corporation | $303.65 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $232.73 | 2019-2021 | |
| Amarin Pharma, INC. | $195.30 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $184.18 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Seqirus USA INC | $165.42 | 2022-2025 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $139.51 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $108.80 | 2022-2025 | Eliquis |
| Gilead Sciences, INC. | $66.35 | 2025 | |
| Phadia US INC. | $47.51 | 2020-2022 | |
| Hologic Sales and Service, LLC | $47.09 | 2020-2024 | Aptima |
| Ironwood Pharmaceuticals, INC | $43.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.17 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $30.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.14 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.68 | 2023 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $17.87 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $17.37 | 2023 | Freestyle Libre 2 |
| Roche Diabetes Care, INC. | $15.56 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.17 | 2025 | Voquezna |
| Redhill Biopharma INC. | $14.47 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.28 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayeh Mirshed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.